BioLife Solutions vs Envista
Add, change or remove companies; up to four.
The short version
- Envista is the larger business, with $2.7B of revenue in fiscal 2025 against $96.2M for BioLife Solutions, about 28 times as much.
- BioLife Solutions grew revenue faster (28.9%, against 8.3%).
- Envista kept more of each dollar of sales as operating profit (8.0% operating margin, against −17.3%).
- BioLife Solutions turned more of its sales into free cash flow (11.1% FCF margin, against 8.5%).
- Envista earned a higher return on the capital invested in it (3.2%, against −4.8%).
| Latest fiscal year | BLFS · FY25 | NVST · FY25 |
|---|---|---|
| Size | ||
| Market cap | — | $3.9B |
| Revenue | $96.2M | $2.7B |
| Free cash flow | $10.6M | $230M |
| Net income | −$4.6M | $47.0M |
| Growth | ||
| Revenue growth | 28.9% | 8.3% |
| 5-year growth | 14.9% | 7.1% |
| Share count change | 5.6% | −1.7% |
| Profitability | ||
| Gross margin | 64.6% | 54.7% |
| Operating margin | −17.3% | 8.0% |
| Net margin | −4.8% | 1.7% |
| FCF margin | 11.1% | 8.5% |
| Return on capital | −4.8% | 3.2% |
| Return on equity | −1.3% | 1.6% |
| Balance sheet | ||
| Net debt | −$83.9M | $237M |
| Net debt / EBITDA | — | 0.7x |
| Dividends and buybacks | $0.0M | $167M |
| Valuation & quality | ||
| P/E | — | 40.7x |
| Piotroski F-score | 6 | 7 |
Revenue
FY16
BLFS $8.2M
NVST —
FY17
BLFS $11.0M
NVST $2.8B
FY18
BLFS $19.7M
NVST $2.8B
FY19
BLFS $27.4M
NVST $2.3B
FY20
BLFS $48.1M
NVST $1.9B
FY21
BLFS $119M
NVST $2.5B
FY22
BLFS $76.2M
NVST $2.6B
FY23
BLFS $68.0M
NVST $2.6B
FY24
BLFS $74.6M
NVST $2.5B
FY25
BLFS $96.2M
NVST $2.7B
BLFS
NVST
Operating margin
FY16
BLFS −59.0%
NVST —
FY17
BLFS −9.6%
NVST 13.8%
FY18
BLFS 18.6%
NVST 10.5%
FY19
BLFS −0.8%
NVST 10.3%
FY20
BLFS −13.0%
NVST 2.3%
FY21
BLFS −29.5%
NVST 12.2%
FY22
BLFS −7.8%
NVST 12.4%
FY23
BLFS −25.3%
NVST 1.2%
FY24
BLFS −6.0%
NVST −41.4%
FY25
BLFS −17.3%
NVST 8.0%
BLFS
NVST
Free cash flow
FY16
BLFS −$4.5M
NVST —
FY17
BLFS $0.5M
NVST $310M
FY18
BLFS $1.9M
NVST $328M
FY19
BLFS $0.5M
NVST $320M
FY20
BLFS $4.7M
NVST $236M
FY21
BLFS −$13.0M
NVST $307M
FY22
BLFS −$18.9M
NVST $107M
FY23
BLFS −$18.9M
NVST $218M
FY24
BLFS $5.2M
NVST $303M
FY25
BLFS $10.6M
NVST $230M
BLFS
NVST
Return on capital
FY16
BLFS —
NVST —
FY17
BLFS —
NVST —
FY18
BLFS —
NVST —
FY19
BLFS —
NVST 3.9%
FY20
BLFS −6.5%
NVST 0.7%
FY21
BLFS −10.5%
NVST 6.0%
FY22
BLFS −1.3%
NVST 5.2%
FY23
BLFS −4.2%
NVST 0.5%
FY24
BLFS −1.2%
NVST −19.9%
FY25
BLFS −4.8%
NVST 3.2%
BLFS
NVST
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.